Literature DB >> 8105156

Differentiation of purified malignant B cells induced by PMA or by activated normal T cells.

C van Kooten1, I Rensink, L Aarden, R van Oers.   

Abstract

We studied the in vitro differentiation (immunoglobulin production) of purified malignant B cells of 21 patients with different B-cell malignancies, including chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), hairy cell leukemia (HCL) and non-Hodgkin lymphoma (NHL). Direct activation of purified malignant B cells with phorbol myristate acetate (PMA) resulted in the differentiation of most CLL cells, but not of the other types of B-cell malignancies. This differentiation required the presence of interleukin 4 (IL-4). In contrast, with the use of anti-CD2-stimulated normal T cells and IL-2, immunoglobulin M (IgM) could be detected in the supernatant of all but one of the purified malignant B-cell populations. However, by analysis of the light chains of the IgM produced, monoclonality could be demonstrated in only 13/21 cases: 8/11 CLL, 3/3 PLL, 0/3 HCL, and 2/4 NHL. In two patients additional proof that the malignant B cells were the source of the IgM production could be obtained in an idiotype-specific ELISA. Apart from IgM, also the production of IgG antibodies could be detected. However, only for 2/3 HCL patients, we could confirm a monoclonal IgG production. Since HCL is a malignancy of mature B cells, already carrying IgG on the membrane, this IgG production is not the result of a switch process. In all other cases where IgG production was polyclonal, we have no indications for the induction of Ig switch. The fact that the more mature B-cell malignancies were T-cell-dependent for their differentiation might be a reflection of the in-vivo situation. The efficient induction of malignant B-cell differentiation described in this paper allows investigation of the antigen specificity of these antibodies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8105156

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  5 in total

Review 1.  In Vitro and In Vivo Models of CLL-T Cell Interactions: Implications for Drug Testing.

Authors:  Eva Hoferkova; Sona Kadakova; Marek Mraz
Journal:  Cancers (Basel)       Date:  2022-06-23       Impact factor: 6.575

2.  TLR9 Ligand (CpG Oligodeoxynucleotide) Induces CLL B-Cells to Differentiate into CD20(+) Antibody-Secreting Cells.

Authors:  Hussein Ghamlouch; Hakim Ouled-Haddou; Aude Guyart; Aline Regnier; Stéphanie Trudel; Jean-François Claisse; Vincent Fuentes; Bruno Royer; Jean-Pierre Marolleau; Brigitte Gubler
Journal:  Front Immunol       Date:  2014-06-16       Impact factor: 7.561

3.  Phorbol myristate acetate, but not CD40L, induces the differentiation of CLL B cells into Ab-secreting cells.

Authors:  Hussein Ghamlouch; Hakim Ouled-Haddou; Aude Guyart; Aline Regnier; Stéphanie Trudel; Jean-François Claisse; Vincent Fuentes; Bruno Royer; Jean-Pierre Marolleau; Brigitte Gubler
Journal:  Immunol Cell Biol       Date:  2014-05-06       Impact factor: 5.126

4.  Factors involved in CLL pathogenesis and cell survival are disrupted by differentiation of CLL B-cells into antibody-secreting cells.

Authors:  Hussein Ghamlouch; Walaa Darwiche; Ahmed Hodroge; Hakim Ouled-Haddou; Sébastien Dupont; Amrathlal Rabbind Singh; Caroline Guignant; Stéphanie Trudel; Bruno Royer; Brigitte Gubler; Jean-Pierre Marolleau
Journal:  Oncotarget       Date:  2015-07-30

Review 5.  Chronic Lymphocytic Leukemia B-Cell Normal Cellular Counterpart: Clues From a Functional Perspective.

Authors:  Walaa Darwiche; Brigitte Gubler; Jean-Pierre Marolleau; Hussein Ghamlouch
Journal:  Front Immunol       Date:  2018-04-04       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.